Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00126906 |
Recruitment Status
:
Completed
First Posted
: August 5, 2005
Last Update Posted
: August 23, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Malaria, Falciparum HIV Infections | Drug: Monthly sulfadoxine/pyrimethamine Drug: 2-dose sulfadoxine/pyrimethamine | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 700 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Educational/Counseling/Training |
Official Title: | Intermittent Preventive Treatment With Sulfadoxine/Pyrimethamine During Pregnancy Among HIV-Positive and HIV-Negative Women: 2-Dose Versus Monthly – Malawi |
Study Start Date : | October 2002 |
Study Completion Date : | March 2005 |

- Placental malaria parasitemia rates measured at time of delivery, stratified by HIV status
- Proportion of newborns with low birth weight, stratified by HIV status
- Proportion of women with third trimester anemia, stratified by HIV status
- Proportion of pregnancies that suffer fetal loss, stratified by HIV status

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- First or second pregnancy
- Greater than 16 weeks gestation
- Less than 28 weeks gestation
- Consent for HIV testing
Exclusion Criteria:
- Less than 15 years old

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00126906
Malawi | |
Machinga District Hospital | |
Liwonde, Malawi |
Principal Investigator: | Scott J Filler, MD, DTM&H | Centers for Disease Control and Prevention |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00126906 History of Changes |
Other Study ID Numbers: |
CDC-NCID-3429 |
First Posted: | August 5, 2005 Key Record Dates |
Last Update Posted: | August 23, 2005 |
Last Verified: | August 2005 |
Keywords provided by Centers for Disease Control and Prevention:
Malaria Pregnancy HIV |
Additional relevant MeSH terms:
HIV Infections Malaria Malaria, Falciparum Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Protozoan Infections Parasitic Diseases |
Pyrimethamine Sulfadoxine Fanasil, pyrimethamine drug combination Antimalarials Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Folic Acid Antagonists Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Infective Agents, Urinary Renal Agents |